Oryzon Genomics S.A. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was EUR 15.7 million compared to EUR 10.62 million a year ago. Net loss was EUR 4.23 million compared to EUR 4.69 million a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.963 EUR | +0.56% | -0.41% | +3.39% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.39% | 121M | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+47.07% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- ORY Stock
- News Oryzon Genomics S.A.
- Oryzon Genomics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022